The "Squawk on the Street" news team reports on today's top business headlines, including the ousting of JC Penney's Ron Johnson and what's at stake for hedge fund manager Bill Ackman.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today, Cramer shares his thoughts on the future of JC Penney.
Kevin Landis, FirstHand Funds, discusses the opportunities available in tapping into public and private mobility companies, and investing in smart phone blue chips.
St. Louis Federal Reserve Bank President James Bullard told CNBC that he's be willing to reduce the central bank's massive bond-buying program in "small increments."
Some of the names on the move ahead of the open.
Len Blum, Westwood Capital; and Kevin Ferry, Cronus Futures Management, share the strategies investors need to know to navigate their way through earnings season.
Sever drought in the U.S. led to sharp increases in global crop prices, but some food stocks offer opportunities for the investors. TheStreet.com offers 6 picks.
CNBC's Ross Westgate reports on all the market moving events from Europe, as stocks rallied, helped by central bank money printing.
Goodyear Tire & Rubber has pulled back to a key support level, and the bulls stepped in yesterday.
CNBC's Ross Westgate tells you what the markets will be watching as we approach the start of trading in the U.S.
With earnings season a potential negative for stocks, traders are even more vigilant than usual for news on the direction of the economy.
Discussing the market's latest moves, and where to put your money now, with Joe Lavorgna, Deutsche Bank and Don Luskin, Trend Macro.
Jim Cramer says his two best speculative ideas for 2013 are just now beginning to make their moves higher. (3:34)
It seems the Street is getting behind two of Cramer’s favorite spec plays.
IPOs are on fire, says Mad Money host Jim Cramer. What kind of IPO is just right for your money? A look at Intelsat and Taylor Morrison Home Corp.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
True many pay dividends, but don’t paint all pharma companies with the same brush.
Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.
Cramer thinks after GE’s acquisition of Lufkin for about $3 billion, other companies may be in play.
GE payed $3.3 billion for Lufkin. Mad Money host Jim Cramer says the purchase is an important step for the company in becoming a dominant player in the oil and natural gas industry.